Work

High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.7_suppl.423

Authors: Sandra Aung, Michael A. Morse, Michael K.K. Wong, Howard Kaufman, Gregory A. Daniels, David F. McDermott

Institutions: Prometheus Biosciences (United States), Duke Medical Center, University of Southern California, Rush University Medical Center, Moores Cancer Center, Beth Israel Deaconess Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1955656308

Cites:

Cited by: 7

Related to: 10